According to Brownstein and his colleagues, the biggest reductions in obesity were seen in women and individuals between the ages of 66 and 75. Obesity rates were significantly.
Decreased among residents in the South, which had the greatest number of prescriptions for GLP-1 receptor agonists, which are medications used to help people lose weight.
The active component of the well-known weight-loss medications Ozempic and Wegovy is semaglutide, which is a member of the family of medications known as GLP-1 agonists.
According to a research published in the Annals of Internal Medicine, the usage of these medications primarily for weight reduction increased by 700% in the United States between 2019 and 2023.
Additionally, they are used to treat type 2 diabetes and obesity-related conditions. According to Brownstein, the rising use of these drugs might be reversing the trends in obesity.
